Literature DB >> 7237460

Ifosfamide treatment of pancreatic cancer.

N Gad-El-Mawla, J L Ziegler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7237460

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  7 in total

Review 1.  Overview of chemotherapy for pancreatic cancer.

Authors:  S G Arbuck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

2.  Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.

Authors:  T Cerny; G Martinelli; A Goldhirsch; F Terrier; R Joss; M F Fey; K W Brunner; A Küpfer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 3.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Ifosfamide chemotherapy for pancreatic carcinoma.

Authors:  L H Einhorn; P J Loehrer
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Authors:  N C Munshi; P J Loehrer; S D Williams; C Langefeld; G Sledge; C R Nichols; B J Roth; A Neuman; W B Walsh; L H Einhorn
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

6.  Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.

Authors:  G Falkson; J J Van Dyk; R Stapelberg; H C Falkson
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 7.  Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.

Authors:  J Matthias Löhr; Stephan L Haas; Jens C Kröger; Helmut M Friess; Raimund Höft; Peter E Goretzki; Christian Peschel; Markus Schweigert; Brian Salmons; Walter H Gunzburg
Journal:  Pharmaceutics       Date:  2014-08-11       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.